Posts tagged ‘ESMO 2011’
September 26th, 2011
It’s exciting to see new products that make a difference to patients come to market. Multiple treatments improve overall survival (OS) in prostate cancer patients: docetaxel, cabazitaxel, sipuleucel-T, abiraterone acetate and now, radium-223 choloride.
The phase 3 trial results for radium 223 chloride were presented at the 2011 European Multidisciplinary Cancer Congress (ESMO, ECCO, ESTRO) in Stockholm this past weekend.
- Alpharadin will be a new treatment option for Prostate Cancer
- Alpharadin Prostate Cancer data will be “practice changing”
He also took the opportunity to interview Dr Chris Parker, Consultant Clinical Oncologist at The Royal Marsden Hospital, who presented the ALSYMPCA phase 3 trial results, and a video blog post will follow.
Sally Church on Pharma Strategy Blog aggregated all the tweets from the 2011 ESMO ECCO congress in Stockholm. With only a few people tweeting, the twitter stream doesn’t report all the news, but does give a flavor of an excellent cancer meeting with a good balance of science and clinical data.
It’s an exciting time for prostate cancer patients and physicians with multiple new treatment options on the horizon. However, the fast moving and dynamic prostate cancer market is likely to present Pharma/Biotech marketing strategy professionals with opportunities and challenges. Alpharadin is on the fast track to FDA approval in 2012.
September 22nd, 2011
The 2011 Stockholm Multidisciplinary Cancer Congress (more commonly known as ECCO 2011 or ESMO 2011) is underway in Stockholm, Sweden.
Pieter Droppert (@3NT) will be writing on Biotech Strategy Blog from the meeting and in particular the new data on prostate cancer that will be presented, in particular the phase 3 Alpharadin ALSYMPCA trial data that is a late breaking abstract.
Sally Church (@MaverickNY) will be covering several sessions live on Twitter. On Pharma Strategy Blog, Sally is aggregating the live tweets from the meeting (#EMCC2011). If you are unable to be in Stockholm for the meeting this weekend, you can follow the action remotely. As Sally would say, “check it out.”
September 9th, 2011
Now that summer is officially over, the fall pharma/biotech conference season has started. You can find out details of the conferences Icarus Consultants will be attending by checking out our conference schedule.
If you are interested in our meeting coverage services or a conference report, please contact us.
This week, we followed two conferences remotely through Twitter. On Biotech Strategy Blog, Pieter Droppert aggregated the tweets from the BioPharm America 2011 partnering conference in Boston.
The joy of twitter is that you can follow the key messages of conference presenters remotely. It’s no substitute for being at the meeting and the networking opportunities in person, but it does allow you to capture a flavor of what everyone is thinking. 140 characters allows for a good sound bite!
Meanwhile on Pharma Strategy Blog, Sally Church has been following the ASCO Breast Cancer Symposium 2011 in San Francisco. Icarus Consultants will be at the San Antonio Breast Cancer Symposium (SABCS) later this year.
On Pharma Strategy Blog, Sally also wrote about the European Multidisciplinary Cancer Conference in Stockholm, more commonly known as ECCO or ESMO. The conference abstracts will be available on Monday, so we look forward to Sally’s video preview and thoughts on what’s hot at the meeting.
August 26th, 2011
The prostate cancer market is dynamic, with a lot of news happening. One of the many new treatments in development worth watching is custirsen (OGX-011).
Sally Church on Pharma Strategy Blog recently wrote about Custirsen from OncoGeneX. This drug inhibits the production of clusterin, a protein associated with the development of treatment resistance. As Sally notes it is in essence a “chemo enhancer.”
Phase 3 trials with custirsen are currently underway in castrate resistant prostate cancer patients receiving docetaxel in the first and second line setting.
The potential to improve the efficacy of docetaxel may be of commercial interest as more generic versions become available. According to IMS Health, sales of generic and branded docetaxel were approximately $1.1 billion for the year from June 2010 to June 2011.
This week Sandoz entered the market with their announcement of the FDA approval and launch of their generic version of Taxotere®.
It will be interesting to see whether use of custirsen with docetaxel increases overall survival (OS) in the phase III CRPC trials, and if it does how this compares to other recently approved CRPC treatments such as Zytiga™ (abiraterone acetate).
As Sally noted in her video blog post from the annual meeting of the American Urological Association (AUA), there is also preliminary scientific data to suggest that custirsen may improve the efficacy of androgen receptor antagonists such as MDV3100 from Medivation/Astellas.
We expect there will be new data on prostate cancer new products in development at the ESMO/ECCO European Multidisciplinary Cancer Congress in Stockholm in late September. The possibility of new treatment options is good news for prostate cancer patients. It is a market definitely worth watching.
August 25th, 2011
Summer is almost over, and thoughts at Icarus Consultants are now turning to forthcoming medical meetings that we will be attending.
We will be at ECCO 16 – ESMO 36 in Stockholm from September 23 – 27, 2011.
The jointly organized multidisciplinary cancer congress of the European CanCer Organisation (ECCO ) and European Society for Medical Oncology (ESMO) covers a wide range of topics from basic and translational science to surgery, radiotherapy, medical oncology, advocacy and care.
You can access the preliminary programme for the meeting here.
Given the early cut-off date for submission of abstracts for the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, we expect the ECCO/ESMO Stockholm meeting will publish interesting data on a number of new products in development.
In anticipation of the meeting, Sally Church will be analyzing the abstracts (once they are available) for what’s hot and you can expect a pre-meeting video blog post. If you missed Sally’s ASCO preview video, it is well worth watching.
Hope to see you in Stockholm.